世界の自己免疫疾患治療市場(~2027年):製品別、用途別、地域別

【英語タイトル】Autoimmune Disease Therapeutics Market Research Report by Product, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが出版した調査資料(360iR22DC205)・商品コード:360iR22DC205
・発行会社(調査会社):360iResearch
・発行日:2022年10月
・ページ数:240
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,949 ⇒換算¥732,452見積依頼/購入/質問フォーム
Enterprise LicenseUSD9,949 ⇒換算¥1,472,452見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

360iResearch社の本調査レポートでは、2021年に1715.8億ドルであった世界の自己免疫疾患治療市場規模が、2022年に1846.7億ドルになり、2027年まで年平均7.8%で成長して2693.3億ドルに達すると予測しています。本レポートでは、自己免疫疾患治療の世界市場を広く調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別(診断装置、治療薬、治療・監視装置)分析、用途別(限局性自己免疫疾患、全身性自己免疫疾患)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などを以下の構成でまとめています。本書では、Abbott Laboratories、AbbVie Inc、Active Biotech、Amgen Inc.、Angiotech Pharmaceuticals、Astellas Pharma Inc、AstraZeneca PLC、Autoimmune Inc、Bayer AG、Bio-rad Laboratories、Biocryst Pharmaceuticals Inc.、Biogen Incなどの企業情報が含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト

・世界の自己免疫疾患治療市場規模:製品別
- 診断装置の市場規模
- 治療薬の市場規模
- 治療・監視装置の市場規模

・世界の自己免疫疾患治療市場規模:用途別
- 限局性自己免疫疾患におけるの市場規模
- 全身性自己免疫疾患における市場規模

・世界の自己免疫疾患治療市場規模:地域別
- 南北アメリカの自己免疫疾患治療市場規模
アメリカの自己免疫疾患治療市場規模
カナダの自己免疫疾患治療市場規模
ブラジルの自己免疫疾患治療市場規模

- アジア太平洋の自己免疫疾患治療市場規模
日本の自己免疫疾患治療市場規模
中国の自己免疫疾患治療市場規模
インドの自己免疫疾患治療市場規模
韓国の自己免疫疾患治療市場規模
台湾の自己免疫疾患治療市場規模

- ヨーロッパ/中東/アフリカの自己免疫疾患治療市場規模
イギリスの自己免疫疾患治療市場規模
ドイツの自己免疫疾患治療市場規模
フランスの自己免疫疾患治療市場規模
ロシアの自己免疫疾患治療市場規模

- その他地域の自己免疫疾患治療市場規模

・競争状況
・企業情報

The Global Autoimmune Disease Therapeutics Market size was estimated at USD 171.58 billion in 2021 and expected to reach USD 184.67 billion in 2022, and is projected to grow at a CAGR 7.80% to reach USD 269.33 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Autoimmune Disease Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Diagnostic Equipment, Drugs, and Therapeutic & Monitoring Equipment. The Drugs is further studied across Aminosalicylates/5-asa/Mesalazine, Anthralin, Avonex, Betaseron, Calicipotriene, Copaxone, Corticosteriods, Glucocorticoids, Hydroxychloroquine (HCQ), Methotrexate, Non-steroidal Anti-inflammatory Drugs (NSAID), and Rebif.

Based on Application, the market was studied across Localized Autoimmune Diseases and Systemic Autoimmune Diseases.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Autoimmune Disease Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Autoimmune Disease Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Autoimmune Disease Therapeutics Market, including Abbott Laboratories, AbbVie Inc, Active Biotech, Amgen Inc., Angiotech Pharmaceuticals, Astellas Pharma Inc, AstraZeneca PLC, Autoimmune Inc, Bayer AG, Bio-rad Laboratories, Biocryst Pharmaceuticals Inc., Biogen Inc, Biomérieux SA, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, F. Hoffmann-la Roche, GlaxoSmithKline PLC, Inova Diagnostics, Inc. by Werfen Group, Johnson & Johnson Services, Inc, Lupin Limited, Myriad Genetics, Novartis AG, Pandion Therapeutics, Pfizer Inc., SC AG, Siemens Healthineers, Inc., Thermo Fisher Scientific, Inc, and Trinity Biotech PLC.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Autoimmune Disease Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Autoimmune Disease Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Autoimmune Disease Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Autoimmune Disease Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Autoimmune Disease Therapeutics Market?
6. What is the market share of the leading vendors in the Global Autoimmune Disease Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Autoimmune Disease Therapeutics Market?

❖ レポートの目次 ❖

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of autoimmune diseases in emerging economies
5.1.1.2. Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
5.1.1.3. Urbanization and availability of high disposable income with the population
5.1.2. Restraints
5.1.2.1. High cost and uncertain outcomes of the treatment
5.1.3. Opportunities
5.1.3.1. Increasing funding by government associations and non-profit organizations for development of new drugs and therapies
5.1.3.2. Automation of laboratories to ease several autoimmune diagnostic tests and availability of autoimmune treatments
5.1.4. Challenges
5.1.4.1. Slow turnaround time associated with the autoimmune disease diagnostics procedures
5.2. Cumulative Impact of COVID-19

6. Autoimmune Disease Therapeutics Market, by Product
6.1. Introduction
6.2. Diagnostic Equipment
6.3. Drugs
6.4.1. Aminosalicylates/5-asa/Mesalazine
6.4.2. Anthralin
6.4.3. Avonex
6.4.4. Betaseron
6.4.5. Calicipotriene
6.4.6. Copaxone
6.4.7. Corticosteriods
6.4.8. Glucocorticoids
6.4.9. Hydroxychloroquine (HCQ)
6.4.10. Methotrexate
6.4.11. Non-steroidal Anti-inflammatory Drugs (NSAID)
6.4.12. Rebif
6.4. Therapeutic & Monitoring Equipment

7. Autoimmune Disease Therapeutics Market, by Application
7.1. Introduction
7.2. Localized Autoimmune Diseases
7.3. Systemic Autoimmune Diseases

8. Americas Autoimmune Disease Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Autoimmune Disease Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Autoimmune Disease Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Abbott Laboratories
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. AbbVie Inc
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Active Biotech
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Amgen Inc.
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Angiotech Pharmaceuticals
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Astellas Pharma Inc
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. AstraZeneca PLC
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Autoimmune Inc
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Bayer AG
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Bio-rad Laboratories
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Biocryst Pharmaceuticals Inc.
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Biogen Inc
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Biomérieux SA
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Bristol-Myers Squibb
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. C.H. Boehringer Sohn AG & Ko. KG
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. F. Hoffmann-la Roche
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. GlaxoSmithKline PLC
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Inova Diagnostics, Inc. by Werfen Group
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Johnson & Johnson Services, Inc
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Lupin Limited
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services
12.21. Myriad Genetics
12.21.1. Business Overview
12.21.2. Key Executives
12.21.3. Product & Services
12.22. Novartis AG
12.22.1. Business Overview
12.22.2. Key Executives
12.22.3. Product & Services
12.23. Pandion Therapeutics
12.23.1. Business Overview
12.23.2. Key Executives
12.23.3. Product & Services
12.24. Pfizer Inc.
12.24.1. Business Overview
12.24.2. Key Executives
12.24.3. Product & Services
12.25. SC AG
12.25.1. Business Overview
12.25.2. Key Executives
12.25.3. Product & Services
12.26. Siemens Healthineers, Inc.
12.26.1. Business Overview
12.26.2. Key Executives
12.26.3. Product & Services
12.27. Thermo Fisher Scientific, Inc
12.27.1. Business Overview
12.27.2. Key Executives
12.27.3. Product & Services
12.28. Trinity Biotech PLC
12.28.1. Business Overview
12.28.2. Key Executives
12.28.3. Product & Services

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing



★調査レポート[世界の自己免疫疾患治療市場(~2027年):製品別、用途別、地域別] (コード:360iR22DC205)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の自己免疫疾患治療市場(~2027年):製品別、用途別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆